Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    Tisotumab Vedotin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Zai Lab Gets Tivdak Approval for Recurrent Cervical Cancer
    Zai Lab Gets Tivdak Approval for Recurrent Cervical Cancer

    01 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250901343152/en/Zai-Lab-Announces-Approval-of-TIVDAK-for-Patients-with-Recurrent-or-Metastatic-Cervical-Cancer-in-Hong-Kong

    BUSINESSWIRE
    01 Sep 2025
    Share Share
    TIVDAK® approved by European Commission for Cervical Cancer
    TIVDAK® approved by European Commission for Cervical Cancer

    31 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/31/3052498/0/en/TIVDAK-tisotumab-vedotin-Approved-by-European-Commission-for-Previously-Treated-Recurrent-or-Metastatic-Cervical-Cancer.html

    GLOBENEWSWIRE
    31 Mar 2025
    Share Share
    Pfizer Inc`s Tivdak Receives Approval in Europe
    Pfizer Inc`s Tivdak Receives Approval in Europe

    28 Mar 2025

    // EMA

    https://www.ema.europa.eu/en/documents/overview/tivdak-epar-medicine-overview_en.pdf

    EMA
    28 Mar 2025
    Share Share
    Tivdak approved by Japan Ministry for Advanced Cervical Cancer
    Tivdak approved by Japan Ministry for Advanced Cervical Cancer

    27 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250326627819/en/TIVDAK-tisotumab-vedotin-Approved-by-Japan-Ministry-of-Health-Labour-and-Welfare-for-the-Treatment-of-Advanced-or-Recurrent-Cervical-Cancer-that-has-Progressed-on-or-after-Chemotherapy

    BUSINESSWIRE
    27 Mar 2025
    Share Share
    Zai Lab Achieves Milestone In Cervical Cancer Treatment Study
    Zai Lab Achieves Milestone In Cervical Cancer Treatment Study

    15 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250115437262/en

    BUSINESSWIRE
    15 Jan 2025
    Share Share
    Tisotumab Vedotin Active In Recurrent/Metastatic HNSCC Patients
    Tisotumab Vedotin Active In Recurrent/Metastatic HNSCC Patients

    03 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240603640244/en

    BUSINESSWIRE
    03 Jun 2024
    Share Share